Telix Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Telix Pharmaceuticals Limited (TLX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income30.893.55-70.74-58.54-34.63
Depreciation & Amortization4.964.603.663.763.77
Stock Based Compensation12.175.995.510.961.81
Change in Working Capital-39.77-22.84-0.68-1.9124.54
Change in Accounts Receivable-35.32-18.67-13.55-5.23-0.25
Change in Inventory-2.00-6.57-3.41-2.05-0.07
Change in Accounts Payable27.1719.9920.705.441.29
Change in Other Working Capital-23.83-13.99-2.511.89-0.15
Other Operating Activities18.8624.4318.7712.596.02
Net Cash from Operating Activities26.6316.28-43.48-43.141.51
Investing Activities
Capital Expenditures-8.86-6.60-4.78-0.97-0.19
Acquisitions-21.47-1.01-0.660.00-0.25
Purchases of Investments-32.17-8.970.000.000.00
Sales/Maturities of Investments-12.20-0.76-4.640.00-0.06
Other Investing Activities-8.95-0.04-1.47-1.01-0.34
Net Cash from Investing Activities-83.65-17.37-11.55-1.98-0.84
Financing Activities
Debt Repayment-1.95-1.51-0.87-0.250.00
Common Stock Issued0.624.53123.052.7527.12
Common Stock Repurchased0.000.00-7.820.000.00
Other Financing Activities-9.21-2.22-5.31-0.60-0.10
Net Cash from Financing Activities395.406.94118.922.0726.32
Summary
Effect of Forex Changes on Cash25.08-1.140.202.390.00
Net Change in Cash363.334.7164.09-40.6525.73
Cash at Beginning of Period76.6379.2614.9956.500.00
Cash at End of Period441.7183.9679.1415.970.00
Free Cash Flow17.779.68-48.26-44.111.32
Supplemental Disclosures
Interest Paid2.930.540.280.140.15
Income Taxes Paid1.746.99-11.30-8.81-8.80